Select Language
HLA-A*02:01 & B2M & Glypican 3
Product Inquiry
HLA-A*02:01 & B2M & Glypican 3 Background
Glypican-3 (GPC3) is also known as Intestinal protein OCI-5, GTR2-2, MXR7, which belongs to the glypican family. Glypican 3 / GPC-3 is highly expressed in lung, liver and kidney. Glypican-3 inhibits the dipeptidyl peptidase activity of DPP4. Glypican-3 may be involved in the suppression/modulation of growth in the predominantly mesodermal tissues and organs, and also may play a role in the modulation of IGF2 interactions with its receptor and thereby modulate its function. The Human HLA-A*0201 Glycipan 3 (FVGEFFTDV) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M and FVGEFFTDV peptide of the Glycipan 3 .
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Vactosertib | TEW-7197; EW-7197; NOV-1301 | Phase 3 Clinical | Medpacto Inc | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Myelodysplastic Syndromes; Carcinoma, Transitional Cell; Myeloproliferative Disorders; Osteosarcoma; Colorectal Neoplasms; Urologic Neoplasms; Esophageal adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma; Adenocarcinoma | Details |
| Bintrafusp alfa | M-7824; GSK-4045154; MSB-0011359C | Phase 3 Clinical | Merck Serono | Brain metastases; Cholangiocarcinoma; Breast Neoplasms; Microsatellite Instability; Vulvar Neoplasms; Sarcoma; Nasopharyngeal Carcinoma; Prostatic Neoplasms; Colorectal Neoplasms; Thymus Neoplasms; Oropharyngeal Neoplasms; Gallbladder Neoplasms; Lung Neoplasms; Prostatic Neoplasms, Castration-Resistant; Lymphoma; Penile Neoplasms; Thymoma; Urogenital Neoplasms; Metastatic breast cancer; Carcinoma, Small Cell; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Neoplasm Metastasis; Sarcoma, Kaposi; Neoplasms, Germ Cell and Embryonal; Stomach Neoplasms; Solid tumours; Hematologic Neoplasms; Head and Neck Neoplasms; Intestinal Neoplasms; Skin Melanoma; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Vaginal Neoplasms; Carcinoma; Carcinoma, Renal Cell; Esthesioneuroblastoma, Olfactory; Anus Neoplasms; Biliary Tract Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Nose Neoplasms; Ganglioglioma; Papillomavirus Infections; Carcinoma, Trans | Details |
| Nisevokitug | NIS-793 | Phase 3 Clinical | Xoma Corp | Kidney Neoplasms; Polycythemia Vera; Pancreatic Neoplasms; Myelodysplastic Syndromes; Breast Neoplasms; Colorectal Neoplasms; Primary Myelofibrosis; Carcinoma, Pancreatic Ductal; Lung Neoplasms; Adenocarcinoma; Thrombocythemia, Essential; Carcinoma, Hepatocellular | Details |
| SB-01 (Spine Biopharma) | SB-01 | Phase 3 Clinical | Spine BioPharma Inc | Intervertebral disc disease; Low Back Pain | Details |
| Livmoniplimab | MGH-8; ARGX-115; AGRX-115; ABBV-151 | Phase 3 Clinical | Argenx Se | Solid tumours; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
| Dalutrafusp alfa | GS-1423; AGEN-1423 | Phase 2 Clinical | Agenus Inc | Liver Neoplasms; Solid tumours; Pancreatic Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal | Details |
| ZSP-1603 | ZSP-1603 | Phase 2 Clinical | Guangdong Zhongsheng Pharmaceutical Co Ltd | Ovarian Neoplasms; Liver Neoplasms; Solid tumours; Carcinoma, Renal Cell; Colonic Neoplasms; Idiopathic Pulmonary Fibrosis; Thyroid Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Nicousamide | XLF-III-43 | Phase 2 Clinical | Institue Of Materia Medica Chinese Academy Of Medical Science | Hypertensive nephropathy; Diabetic Nephropathies | Details |
| Meflonidone hydrochloride | Phase 2 Clinical | Guangzhou Nanxin Pharma Co Ltd, Central South University | Diabetes Mellitus, Type 2; Diabetic Nephropathies | Details | |
| Fluorofenidone | AKF-PD | Phase 2 Clinical | Dierepharma HK Ltd, Hainan Haiyao Co Ltd, Central South University | Liver Cirrhosis | Details |
| Cotsiranib | STP-705LU; STP-705LV; STP-705; STP-705L | Phase 2 Clinical | Sirnaomics, Sirnaomics Biopharmaceuticals (Suzhou) Co Ltd | Liver Neoplasms; Carcinoma, Basal Cell; Carcinoma, Basosquamous; Cholangiocarcinoma; Obesity, Abdominal; Keloid; Cicatrix, Hypertrophic; Carcinoma, Hepatocellular | Details |
| Yinfenidone Hydrochloride | HEC-585; HEC-00000585 | Phase 2 Clinical | Hec Pharm Co Ltd | Idiopathic Pulmonary Fibrosis; Lung Diseases, Interstitial | Details |
| YL-13027 | YL-13027 | Phase 2 Clinical | YL-Pharma | Solid tumours; Pancreatic Neoplasms | Details |
| Linavonkibart | SRK-181 | Phase 1 Clinical | Scholar Rock | Neoplasms | Details |
| Charis-1000 | Charis-1000; C 1K; C1K | Phase 1 Clinical | Breast Neoplasms | Details | |
| HLX-6018 | HLX-6018; HLX6018 | Phase 1 Clinical | Idiopathic Pulmonary Fibrosis | Details | |
| RO7496353 | RO7496353; RO-7496353; SOF 10; RG6440; RG-6440 | Phase 1 Clinical | Genentech Inc | Solid tumours; Stomach Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung | Details |
| JYB-1907 | JYB-1907 | Phase 1 Clinical | Jiangxi Jemincare Group Co Ltd | Solid tumours | Details |
| STP-707 | STP-707 | Phase 1 Clinical | Sirnaomics Biopharmaceuticals (Suzhou) Co Ltd | Solid tumours; Liver Neoplasms; Liver Cirrhosis; Pulmonary Fibrosis; Cholangitis, Sclerosing | Details |
| PXS-64 | PXS-64 | Phase 1 Clinical | Multiple Sclerosis | Details | |
| AVID-200 | AVID-200; BMS-986416; AVID-200 DP | Phase 1 Clinical | Formation Biologics Corp | Solid tumours; Polycythemia Vera; Primary Myelofibrosis; Scleroderma, Diffuse; Thrombocythemia, Essential | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Tonogenchoncel-L | TG-C | Approved | Tissuegene | Invossa-K, Invossa | South Korea | Osteoarthritis | null | 2017-07-01 | Intervertebral Disc Degeneration; Osteoarthritis, Knee; Osteoarthritis | Details |
- Product Inquiry
- Marketed Drug Information
- Clinical Drug Information
Share to: